Related Experiment Video
Updated: May 30, 2026
Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
The genomics of lung adenocarcinoma: opportunities for targeted therapies
1Dana-Farber Cancer Institute, Boston, MA, USA.
Abstract:
Standard cytotoxic chemotherapy is effective for some cancers, but for many others, available treatments offer only a limited survival benefit. Lung adenocarcinoma is one such cancer, responsible for approximately half of lung cancer deaths each year. Development of targeted therapies is thought to hold the most promise for successfully treating this disease, but a targeted approach is dependent on understanding the genomic state of the tumor cells. Exon-directed sequencing of large numbers of lung adenocarcinoma tumor samples has provided an initial low-resolution image of the somatic mutation profile of these tumors. Such cancer sequencing studies have confirmed the high frequency of TP53 and KRAS mutations in lung adenocarcinoma, have found inactivating mutations in known tumor suppressor genes not previously associated with lung adenocarcinoma, and have identified oncogenic mutations of EGFR upon which the first targeted therapy for lung adenocarcinoma patients was based. Additional candidate oncogenes await functional validation. It is anticipated that upcoming whole-exome and whole-genome lung adenocarcinoma sequencing experiments will reveal a more detailed landscape of somatic mutations that can be exploited for therapeutic purposes.
Insights
Understanding the genomic mutations in lung adenocarcinoma is key to developing targeted therapies. Sequencing tumor samples reveals common mutations like TP53 and KRAS, paving the way for more effective cancer treatments.
Area of Science:
- Oncology
- Genomics
- Cancer Research
Background:
- Lung adenocarcinoma causes significant mortality, with limited survival benefits from standard chemotherapy.
- Targeted therapies offer promise but require detailed knowledge of tumor cell genomic alterations.
- Current understanding of lung adenocarcinoma's somatic mutation profile is based on initial exon-directed sequencing.
Purpose of the Study:
- To analyze the somatic mutation profile of lung adenocarcinoma tumors.
- To identify actionable mutations for targeted therapy development.
- To lay the groundwork for future whole-exome and whole-genome sequencing studies.
Main Methods:
- Exon-directed sequencing of numerous lung adenocarcinoma tumor samples.
- Analysis of somatic mutation profiles to identify frequently mutated genes.
- Comparison with existing knowledge of cancer-associated genes.
Main Results:
- Confirmed high frequencies of TP53 and KRAS mutations.
- Identified inactivating mutations in previously unassociated tumor suppressor genes.
- Discovered oncogenic EGFR mutations, enabling the first targeted therapy.
Conclusions:
- Genomic sequencing is crucial for advancing lung adenocarcinoma treatment.
- Further whole-exome and whole-genome sequencing will refine the landscape of actionable mutations.
- Exploiting detailed genomic information holds promise for improved therapeutic strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:29Pharmacogenomics: Identification of New Drug Targets
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase